A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer

J. Weber, H. Gunn, J. Yang, D. Parkinson, Suzanne Topalian, D. Schwartzentruber, S. Ettinghausen, D. Levitt, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Eighteen patients were treated with escalating doses of recombinant, Escherchia coli-derived human interleukin-6 (IL-6) intravenously every 8 h. Therapy was given for two cycles of 7 days each separated by a week off therapy. Fevers and chills were observed in most patients. Mild renal and liver function abnormalities were noted at higher doses of IL-6. Dose-limiting toxicity was reached at 30 μg/kg i.v. every 8 h due to reversible neurotoxicity, but significant rapidly reversible anemia and hyperglycemia were seen at lower doses. Platelet counts, white blood cell counts, and acute phase reactant levels were substantially elevated. No antitumor responses were seen. A maximum tolerated dose of 10 μg/kg i.v. every 8 h for two 7-day cycles is recommended for future phase II trials.

Original languageEnglish (US)
Pages (from-to)292-302
Number of pages11
JournalJournal of Immunotherapy
Volume15
Issue number4
StatePublished - 1994
Externally publishedYes

Fingerprint

Interleukin-6
Chills
Maximum Tolerated Dose
Acute-Phase Proteins
Platelet Count
Leukocyte Count
Hyperglycemia
Anemia
Neoplasms
Fever
Kidney
Liver
Therapeutics

Keywords

  • Advanced cancer.
  • IL-6
  • Phase I trial

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Weber, J., Gunn, H., Yang, J., Parkinson, D., Topalian, S., Schwartzentruber, D., ... Rosenberg, S. A. (1994). A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer. Journal of Immunotherapy, 15(4), 292-302.

A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer. / Weber, J.; Gunn, H.; Yang, J.; Parkinson, D.; Topalian, Suzanne; Schwartzentruber, D.; Ettinghausen, S.; Levitt, D.; Rosenberg, S. A.

In: Journal of Immunotherapy, Vol. 15, No. 4, 1994, p. 292-302.

Research output: Contribution to journalArticle

Weber, J, Gunn, H, Yang, J, Parkinson, D, Topalian, S, Schwartzentruber, D, Ettinghausen, S, Levitt, D & Rosenberg, SA 1994, 'A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer', Journal of Immunotherapy, vol. 15, no. 4, pp. 292-302.
Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D et al. A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer. Journal of Immunotherapy. 1994;15(4):292-302.
Weber, J. ; Gunn, H. ; Yang, J. ; Parkinson, D. ; Topalian, Suzanne ; Schwartzentruber, D. ; Ettinghausen, S. ; Levitt, D. ; Rosenberg, S. A. / A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer. In: Journal of Immunotherapy. 1994 ; Vol. 15, No. 4. pp. 292-302.
@article{7e9b18f09eb745b994186b4af70d1785,
title = "A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer",
abstract = "Eighteen patients were treated with escalating doses of recombinant, Escherchia coli-derived human interleukin-6 (IL-6) intravenously every 8 h. Therapy was given for two cycles of 7 days each separated by a week off therapy. Fevers and chills were observed in most patients. Mild renal and liver function abnormalities were noted at higher doses of IL-6. Dose-limiting toxicity was reached at 30 μg/kg i.v. every 8 h due to reversible neurotoxicity, but significant rapidly reversible anemia and hyperglycemia were seen at lower doses. Platelet counts, white blood cell counts, and acute phase reactant levels were substantially elevated. No antitumor responses were seen. A maximum tolerated dose of 10 μg/kg i.v. every 8 h for two 7-day cycles is recommended for future phase II trials.",
keywords = "Advanced cancer., IL-6, Phase I trial",
author = "J. Weber and H. Gunn and J. Yang and D. Parkinson and Suzanne Topalian and D. Schwartzentruber and S. Ettinghausen and D. Levitt and Rosenberg, {S. A.}",
year = "1994",
language = "English (US)",
volume = "15",
pages = "292--302",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer

AU - Weber, J.

AU - Gunn, H.

AU - Yang, J.

AU - Parkinson, D.

AU - Topalian, Suzanne

AU - Schwartzentruber, D.

AU - Ettinghausen, S.

AU - Levitt, D.

AU - Rosenberg, S. A.

PY - 1994

Y1 - 1994

N2 - Eighteen patients were treated with escalating doses of recombinant, Escherchia coli-derived human interleukin-6 (IL-6) intravenously every 8 h. Therapy was given for two cycles of 7 days each separated by a week off therapy. Fevers and chills were observed in most patients. Mild renal and liver function abnormalities were noted at higher doses of IL-6. Dose-limiting toxicity was reached at 30 μg/kg i.v. every 8 h due to reversible neurotoxicity, but significant rapidly reversible anemia and hyperglycemia were seen at lower doses. Platelet counts, white blood cell counts, and acute phase reactant levels were substantially elevated. No antitumor responses were seen. A maximum tolerated dose of 10 μg/kg i.v. every 8 h for two 7-day cycles is recommended for future phase II trials.

AB - Eighteen patients were treated with escalating doses of recombinant, Escherchia coli-derived human interleukin-6 (IL-6) intravenously every 8 h. Therapy was given for two cycles of 7 days each separated by a week off therapy. Fevers and chills were observed in most patients. Mild renal and liver function abnormalities were noted at higher doses of IL-6. Dose-limiting toxicity was reached at 30 μg/kg i.v. every 8 h due to reversible neurotoxicity, but significant rapidly reversible anemia and hyperglycemia were seen at lower doses. Platelet counts, white blood cell counts, and acute phase reactant levels were substantially elevated. No antitumor responses were seen. A maximum tolerated dose of 10 μg/kg i.v. every 8 h for two 7-day cycles is recommended for future phase II trials.

KW - Advanced cancer.

KW - IL-6

KW - Phase I trial

UR - http://www.scopus.com/inward/record.url?scp=0028364587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028364587&partnerID=8YFLogxK

M3 - Article

C2 - 7520334

AN - SCOPUS:0028364587

VL - 15

SP - 292

EP - 302

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 4

ER -